Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study

Pauliat E., Onken M., Weber-Schoendorfer C., Rousson V., Addor M., Baud D., ...Daha Fazla

MULTIPLE SCLEROSIS JOURNAL, 2020 (SCI İndekslerine Giren Dergi) identifier identifier


This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-beta-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-beta group (odds ratio, 2.2; 95% confidence interval, 0.2-24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-beta-exposed pregnancies was 0.6 (95% confidence interval, 0.2-1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.